Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Members of the Infectious Disease Society of America highlighted clinical implications in wake of the ACIP meeting.

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers. The de ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

While Moderna does not have specific revenue projections for its individual products, Hoge said Covid, flu and respiratory syncytial virus are each multi-billion-dollar markets. "We're obviously ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...